Zoetis Inc.

Zoetis Inc.

ZTS·NYSE

$77.59

+0.039%
HealthcareDrug Manufacturers - General

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

At a Glance

Live Snapshot
Market Cap$32.53B
EPS6.0300
P/E Ratio12.87
Earnings Date08/04/2026
21.54%
Return on Invested Capital
-3%
3Y+21.0%
5Y+39.0%
10Y+50.0%
80.25%
Return on Equity
54%
3Y+67.0%
5Y+85.0%
10Y+45.0%
17.28%
Return on Assets
-1%
3Y+22.0%
5Y+44.0%
10Y+61.0%
Zoetis Inc.

Zoetis Inc. Management Team

ZTS · NYSE
MK

Ms. Kristin C. Peck

Chief Executive Officer & Director

Compensation

$4,456,913

Born 1971(Age 55)
female
MJ

Mr. Jamie Brannan

Executive Vice President & Chief Commercial Officer

Compensation

$1,809,996

Born 1973(Age 53)
male
MK

Mr. Keith Sarbaugh

Executive Vice President & Chief Digital and Technology Officer

Born 1979(Age 47)
male
MW

Mr. Wetteny N. Joseph CPA

Executive Vice President & Chief Financial Officer

Compensation

$1,902,146

Born 1972(Age 54)
male
MN

Mr. Nick Ashton

Executive Vice President and President of Global Manufacturing & Supply

Born 1973(Age 53)
male
DR

Dr. Robert J. Polzer Ph.D.

Executive Vice President and President of Research & Development

Compensation

$1,523,134

Born 1969(Age 57)
MJ

Ms. Jeannette Ferran Astorga

Executive Vice President of Corporate Affairs & Chief Sustainability Officer

Born 1975(Age 51)
female
MJ

Ms. Julie A. Fuller

Executive Vice President, Chief Human Resources Officer & Global Operations

Born 1972(Age 54)
female
MR

Ms. Roxanne Lagano

Executive Vice President, General Counsel & Corporate Secretary

Compensation

$1,365,476

Born 1965(Age 61)
female
MS

Mr. Steven Frank

Vice President of Investor Relations

male
zts

Zoetis Inc. Insider Positioning

ZTS · NYSE

During the last 12 months, insiders have purchased $886K and sold $1.16M worth of ZTS shares, resulting in $277K of net selling activity.

3 Months

Bought

11.7K

886.37K

Sold

0

0.00

Net Activity

+886K

+$886K

3-6 Months

Bought

0

0.00

Sold

9.2K

1.16M

Net Activity

-1.2M

-$1.16M

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
DFA

Damelio Frank A

Director

6.7K shares1 transactions

$501K

2
MMB

Mccallister Michael B

Director

3.0K shares1 transactions

$233K

3
BP

Bisaro Paul

Director

2.0K shares1 transactions

$152K

Top Sellers

1
PKC

Peck Kristin C

Director, Officer: Chief Executive Officer

9.2K shares1 transactions

$1.16M

Insider Activity Analysis

Net Insider Sentiment

Bearish

Slightly bearish with $277K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.

Buy/Sell Ratio

0.76:1

Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.

Recent Trend (3 Months)

$886K

Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.

Insider Participation

High Buying

3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.

SEC Filings

ZTS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
DEF 14A

DEF 14A 2025

N/A

April 09, 2025
May 21, 2025
2025
DEF 14A

DEF 14A 2024

N/A

April 10, 2024
May 22, 2024
2024
DEF 14A

DEF 14A

N/A

April 06, 2023
April 06, 2023
 
DEF 14A

DEF 14A 2022

N/A

April 06, 2022
May 19, 2022
2022
DEF 14A

DEF 14A 2021

N/A

April 06, 2021
May 20, 2021
2021
DEF 14A

DEF 14A 2020

N/A

April 06, 2020
May 20, 2020
2020
DEF 14A

DEF 14A 2019

N/A

April 02, 2019
May 15, 2019
2019
DEF 14A

DEF 14A 2018

N/A

April 02, 2018
May 15, 2018
2018
DEF 14A

DEF 14A 2017

N/A

March 31, 2017
May 11, 2017
2017
Showing 1 to 10 of 13 filings